Dynabac

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Company:

Approval Status:

Approved March 1998

Specific Treatments:

acute bacterial exacerbations

General Information

Dynabac, a member of the newer macrolide group of antibiotics, has received approval for expanded coverage within certain indications, including the treatment of acute bacterial exacerbations of chronic bronchitis and uncomplicated skin and skin structure infections. Dynabac remains a once-a-day therapy.

Side Effects

The most common side effects were gastrointestinal, including abdominal pain, nausea, and diarrhea.